HLB SCIENCE Inc. (XKON:343090)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,070.00
-25.00 (-1.19%)
At close: Dec 15, 2025
7.25%
Market Cap37.38B
Revenue (ttm)n/a
Net Income (ttm)-2.55B
Shares Out17.84M
EPS (ttm)-566.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume304
Average Volume15,727
Open2,080.00
Previous Close2,095.00
Day's Range2,015.00 - 2,080.00
52-Week Range978.00 - 2,520.00
Beta0.19
RSI58.06
Earnings Daten/a

About HLB SCIENCE

HLB SCIENCE Inc. develops biological drugs with MoA to infectious diseases. Its pipeline includes DD-S052P, a candidate that exterminates germs and eliminates endotoxins; DD-A279, a new treatment to cure Alzheimer's Diseases by controlling LPS and Gram-negative bacteria; and DD-A514, a diagnosis kit for Alzheimer's diseases. The company was formerly known as Dandi Bio Science Co.,Ltd. and changed its name to HLB SCIENCE Inc. in March 2023. The company was founded in 2016 and is based in Seoul, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange Korea New Exchange
Ticker Symbol 343090
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.